Even in a Favorable Regulatory Environment, Will Biosimilars Gain Traction in the US This Year?

Posted by Pratap Khedkar on Fri, Jan 25, 2019

Christina Corridon co-wrote this blog post with Pratap Khedkar.

Despite 16 approvals in the last four years, just six biosimilars currently are being marketed stateside. The U.S. biosimilars market hasn’t progressed as anticipated, yet some experts are wondering whether the biologic follow-ons can redeem themselves with a breakout year in 2019.

The U.S. biosimilars market has a tough road ahead. The WAC list price differential between biosimilars and the originator drugs is hovering around 30%, on average, which likely isn’t speeding biosimilars’ adoption in the U.S. Rather than playing the long game and waiting for the U.S. landscape to become more attractive, some biosimilar manufacturers like Momenta are choosing to exit the market. And others like Pfizer have shuttered their preclinical biosimilar programs to focus their efforts elsewhere. On the flip side, the Trump administration has zeroed in on drug pricing and biosimilars as priorities—and, of course, the two are intertwined.


>
Read More

Physicians, Payers and Patients Want Evidence, and Med Affairs Knows How to Deliver

Posted by Pratap Khedkar on Wed, Jan 16, 2019

As the pharmaceutical industry continues to stack up scientific breakthroughs, there’s a growing need for experts within pharma organizations who can articulate deep disease knowledge, link clinical results to outcomes, and demonstrate product value. As luck would have it, a small department that’s well suited to the task has steadily been building its capabilities and expanding its reach into new areas. Medical affairs, once a little-known entity, is making its mark on the industry, but if leveraged properly, its impact could be even greater.


>
Read More

Pharma’s Commercial Resource Redesign: Managing Timelines and Expectations

Posted by Pratap Khedkar on Wed, Dec 05, 2018

This is the final post in a three-part series on commercial resource planning.

As pharma companies begin to think about reorganizing and deploying their commercial resources to better align with changing customers and an evolving healthcare landscape, their strategy for transforming commercial resource planning can’t be piecemeal, but their approach to implementing the change likely should be. It’s going to take time to develop the right customized approach to suit your company’s specific needs and challenges, and to get buy-in. Data and technology will carry some of the weight, as will coordinating internal processes and roles, and adopting an on-demand, customer-specific mindset.


>
Read More

Pharma Should Be Making More Data-Driven Deployment Decisions

Posted by Pratap Khedkar on Wed, Nov 28, 2018

This is the second post in a three-part series on commercial resource planning.

As the pharma industry’s customers evolve with the shifts in the healthcare landscape, pharma companies can no longer take a static, semiannual, one-size-fits-all approach to commercial resource planning. They need to take an agile, localized, customized approach to aligning commercial resources to better meet their customers’ evolving needs—and they need the right analytics capability to mine the customer and market insights they need to get it done.


>
Read More

If AI Is the Engine and Patient Data Is its Fuel, Then Who’s in the Driver’s Seat?

Posted by Paul Darling on Wed, Oct 31, 2018

Pratap Khedkar co-wrote this blog post, the third in a series on ZS’s 2018 AI in Healthcare study, with Paul Darling.

Each time you visit the doctor, it’s the same scenario: You rattle off a bunch of information like medical history, lifestyle behaviors and choices, and current complaints, while she pounds away at a keyboard. You might have access to a portion of your medical record through a web-based patient portal, but otherwise that content is under the provider’s lock and key (unless you’re a New Hampshire resident). Don’t you wonder what your full electronic health record holds? Stakeholders throughout the healthcare ecosystem do, too.


>
Read More